A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis

Area of Science:

• Pediatrics
• Infectious Diseases
• Pharmacology

Background:

• Bronchiolitis is a common infant respiratory infection and a leading cause of childhood hospitalization.
• Corticosteroid use for bronchiolitis is common, but evidence supporting its efficacy is limited.

Purpose of the Study:

• To evaluate the effectiveness of a single oral dose of dexamethasone in treating moderate-to-severe bronchiolitis in infants.
• To determine if dexamethasone impacts hospital admission rates, respiratory status, or subsequent medical outcomes.

Main Methods:

• A double-blind, randomized trial involving 600 infants (2-12 months) with moderate-to-severe bronchiolitis.
• Comparison of a single 1 mg/kg oral dose of dexamethasone versus placebo.
• Primary outcome: hospital admission after 4-hour emergency department observation; secondary outcomes included respiratory status and later medical events.

Main Results:

• Hospital admission rates were similar: 39.7% for dexamethasone vs. 41.0% for placebo (absolute difference -1.3%).
• No significant difference in respiratory improvement after 4 hours (mean RACS -5.3 vs. -4.8).
• Multivariate analysis and evaluation of later outcomes (hospital stay, subsequent visits/admissions) showed no significant differences between groups.

Conclusions:

• A single oral dose of dexamethasone does not significantly alter hospital admission rates in infants with acute moderate-to-severe bronchiolitis.
• Dexamethasone did not improve respiratory status after 4 hours of observation or affect later medical outcomes.
• The findings suggest limited benefit of this corticosteroid regimen for hospitalized infants with bronchiolitis.